Chelation Therapy - OpenPayer

Coverage Summary & Rationale

UnitedHealthcare medical policy addressing coverage and evidence for chelation therapy for heavy metal toxicity/overload and for non-overload conditions (including dental amalgam mercury). This policy part is effective July 1, 2025 and includes coverage rationale, evidence summaries, guideline and FDA position statements, and applicable procedure/drug codes. Coverage stance is mixed: chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary, while chelation therapy for chronic, progressive non-overload conditions and for alleged mercury 'toxicity' from dental amalgam fillings is unproven and not medically necessary due to insufficient evidence of efficacy.

Policy metadata

Effective DateJuly 1, 2025

Policy Number2025T0051CC

StatusCURRENT

CoversPolicy covers overload/poisoning indications (heavy metal toxicity and overload: iron, copper, lead, aluminum) as proven and medically necessary

ExcludesPolicy excludes chelation for non-overload conditions and dental amalgam mercury 'toxicity' as unproven and not medically necessary

Provider Requirements & Administrative Guidance

Documentation Required

Document indication for overload/toxicity

For coverage, document a diagnosis of heavy metal toxicity or overload (e.g., iron, copper, lead, aluminum) demonstrated with appropriate validated testing in biological samples. Include the applicable HCPCS/J‑codes when submitting claims: J0470, J0600, J0895, J3520, M0300, S9355 (listed for reference). Note that chelation for these documented overload/toxicity indications is considered medically necessary per policy.

Document validated testing in biological samples demonstrating overload/toxicity
Include applicable procedure/drug codes on claims (see codes list)

Denial Risk

Not covered for non-overload conditions or dental amalgam mercury 'toxicity'

Chelation therapy to treat chronic progressive non‑overload diseases (for example, cardiovascular disease, Alzheimer's disease, autism spectrum disorder, Parkinson's disease, diabetes, cancer, rheumatoid arthritis) or to treat alleged mercury 'toxicity' from dental amalgam fillings is considered unproven and not medically necessary and may be denied. Provide objective documentation showing the indication is an FDA‑approved or otherwise covered overload/toxicity condition to avoid claim denial.

Applicable Codes (reference)

Applicable HCPCS / J-codes (reference only)HCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg

Community Plan / Additional codesmixed

J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

No specific procedure/drug/billing codes in this document partmixed

No codes listed

Clinical Evidence, Guidelines & Regulatory Positions

Chelation therapy removes heavy metals using specific chelating agents; the FDA approves chelators for defined indications such as metal poisoning and iron overload, and the policy reviews systematic reviews and randomized trials across both overload and non-overload uses. The evidence section summarizes multiple RCTs and systematic reviews showing efficacy and acceptable safety of iron chelators (DFP, DFX, DFO) in transfusion-related iron overload and related conditions, including large randomized noninferiority trials and meta-analyses. Policy review also covers trials and systematic reviews of EDTA-based chelation for cardiovascular disease (e.g., TACT, TACT2) and concludes that while some trials show reductions in blood lead levels, high-quality evidence does not demonstrate consistent reductions in cardiovascular events. Specialty society guidance and FDA safety communications are summarized and considered in the policy evaluation.

Citation	Summary
Lee et al. (2024)	Systematic review of iron‑chelation therapy (ICT) in thalassemia: compliance ranged 20.9–75.3% overall and varied by agent (DFO 48.8–85.1%, DFP 87.2–92.2%, DFX 90–100%); better compliance correlated with lower ferritin, reduced liver and cardiac complications, and improved HRQoL; authors call for larger studies
Salem et al. (2023)	Systematic review of combined DFP+DFX in iron‑overload: single‑arm studies showed reductions in serum ferritin and LIC; comparative studies found no significant difference versus other regimens; combination generally tolerable with limited reported serious AEs; evidence limited by small sample sizes and study quality
Kwiatkowski et al. (2022)	Randomized open‑label noninferiority trial: oral deferiprone (DFP) noninferior to subcutaneous deferoxamine (DFO) for liver iron concentration at 12 months in transfused patients; similar safety profiles with listed AEs (eg, abdominal pain, vomiting, neutropenia, agranulocytosis)
Maggio et al. (2020)	Multicenter randomized phase 3 trial in pediatric transfusion‑dependent hemoglobinopathies: DFP noninferior to DFX over 12 months for composite efficacy endpoints (serum ferritin and cardiac MRI T2*); no significant difference in serious or drug‑related AEs; supports DFP as an oral option
Yang et al. (2022)	Systematic review/meta‑analysis in low‑ to intermediate‑risk MDS: ICT associated with longer median overall survival, reduced mortality risk and decreased cardiac injury in several observational studies; authors note inability to discern relative efficacy between ICT agents and call for consideration of ICT in select patients
Lamas et al. / TACT2 (2024)	TACT2 multicenter double‑masked RCT of 40 weekly EDTA‑based infusions ± high‑dose vitamins in post‑MI patients with diabetes: EDTA lowered blood lead levels but did not reduce composite cardiovascular events versus placebo; limitations included adherence and loss to follow‑up
Cochrane (Villarruz‑Sulit et al. 2020)	Cochrane review of EDTA chelation for ASCVD (5 RCTs, 1,993 participants): overall insufficient evidence to determine effectiveness on mortality or cardiovascular events; no major AEs reported; authors conclude evidence does not support routine use
TACT and related publications (Lamas et al., 2013; TACT analyses)	TACT (2013) and subsequent subgroup/post‑hoc analyses suggested possible benefit in diabetics or anterior MI subgroups, prompting TACT2 to further evaluate; findings considered exploratory and hypothesis‑generating
FDA communications (2020, 2019)	FDA: approved chelating agents indicated for specific uses (eg, lead poisoning, iron overload); 2020 guidance identifies high‑risk groups who should avoid dental amalgam when possible; 2019 warning against claims that chelation treats autism; chelators are prescription‑only
Mercury / Dental Amalgam evidence (Patini et al. 2020; RCTs)	High‑quality indirect evidence and RCTs show dental amalgam restorations do not cause broad harm; no studies support chelation for alleged amalgam 'toxicity'; systematic review/meta‑analysis found insufficient evidence that amalgam causes nephrotoxicity
Policy revisions / Title change (2025T0051CC)	Policy updated effective 07/01/2025: title changed and coverage rationale clarified that chelation for heavy metal toxicity and overload conditions is proven and medically necessary; prior version archived

FDA guidance re: dental amalgam (DA)

FDA identifies high-risk groups who should avoid dental amalgam when possible:

High-risk groups

Pregnant women and their developing fetuses
Planning pregnancy: Women who are planning to become pregnant

Definitions

Non-overload conditionsConditions where acute or chronic heavy metal toxicity has not been demonstrated and removal of metals is hypothesized to have therapeutic effect (e.g., CVD, Alzheimer's, autism)

Dental amalgam (DA)Mercury-containing dental restorative material; high-quality evidence does not support harm from DA except rare allergy

Medicare / Regulatory Notes

Medicare/coverage guidance information is provided for informational purposes: the policy notes that FDA approval alone is not a basis for coverage and that FDA-approved chelating agents are indicated for metal poisoning and iron overload; use should be limited to FDA-approved indications as referenced in recognized drug compendia. Providers are advised to check applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and other federal or state mandates, and to follow the provider action guidance (including documenting validated testing for overload/toxicity) when seeking coverage decisions.

Policy Revision History

2025-07-01material_changeLatest

Title changed from 'Chelation Therapy for Non-Overload Conditions' and Coverage Rationale updated: replaced prior language with statement that chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary.

2025-07-01archived_previous_policy

Previous policy version 2025T0051BB archived; Clinical Evidence and References sections updated to reflect current information.